|Clinical Trial Title||LUMINA|
|Trial Status||Open to Enrollment|
|Specific Condition||Active, Non-Infectious Uveitis|
This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye.
There is a 6-month, single-arm, open-label period after completion of the 6-month double- masked, controlled period allows the evaluation of the efficacy and safety of intravitreal injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo or sham control.
Ages Eligible for Study: 18 years and older
Sexes Eligible for Study: All
Non-Infectious Active Uveitis of the Posterior Segment
Females who are pregnant, nursing, or planning a pregnancy Confirmed or suspected infectious uveitis
|Principal Investigator||Sirichai Pasadhika, MD|
|Contact Name||Tammy Mayfield|